- Home
- LDI vs TVRD Comparison
LDI vs TVRD Comparison
Compare LDI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- TVRD
- Stock Information
- Founded
- LDI 2010
- TVRD 2017
- Country
- LDI United States
- TVRD United States
- Employees
- LDI N/A
- TVRD N/A
- Industry
- LDI Finance: Consumer Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- TVRD Health Care
- Exchange
- LDI Nasdaq
- TVRD Nasdaq
- Market Cap
- LDI 221.2M
- TVRD 246.5M
- IPO Year
- LDI 2021
- TVRD N/A
- Fundamental
- Price
- LDI $1.31
- TVRD $28.34
- Analyst Decision
- LDI Sell
- TVRD Strong Buy
- Analyst Count
- LDI 3
- TVRD 2
- Target Price
- LDI $1.98
- TVRD $52.00
- AVG Volume (30 Days)
- LDI 735.5K
- TVRD 48.4K
- Earning Date
- LDI 05-06-2025
- TVRD 05-13-2025
- Dividend Yield
- LDI N/A
- TVRD N/A
- EPS Growth
- LDI N/A
- TVRD N/A
- EPS
- LDI N/A
- TVRD N/A
- Revenue
- LDI $1,090,719,000.00
- TVRD N/A
- Revenue This Year
- LDI $28.75
- TVRD N/A
- Revenue Next Year
- LDI $15.05
- TVRD N/A
- P/E Ratio
- LDI N/A
- TVRD N/A
- Revenue Growth
- LDI 21.07
- TVRD N/A
- 52 Week Low
- LDI $1.01
- TVRD $8.13
- 52 Week High
- LDI $3.23
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- LDI 60.49
- TVRD N/A
- Support Level
- LDI $1.18
- TVRD N/A
- Resistance Level
- LDI $1.36
- TVRD N/A
- Average True Range (ATR)
- LDI 0.08
- TVRD 0.00
- MACD
- LDI 0.02
- TVRD 0.00
- Stochastic Oscillator
- LDI 81.48
- TVRD 0.00
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.